Inozyme Pharma, Inc. (INZY) Research

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

Market snapshot

Symbol
INZY
Price
$4.00
Day change
+0.25%
Market cap
$258.2M
P/E ratio
-4.67x
52-week range
0.721-6.24
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$12.00

Peer companies

  • Catabasis Pharmaceuticals, Inc. (CATB)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • LakeShore Biopharma Co., Ltd (LSBCF)
  • scPharmaceuticals Inc. (SCPH)
  • Acelyrin, Inc. (SLRN)
  • Spectrum Pharmaceuticals, Inc. (SPPI)
  • Alaunos Therapeutics, Inc. (TCRT)
  • Third Harmonic Bio, Inc. (THRD)

Recent insider activity

  • Subramanian Sanjay — D-Return (180000 shares) on 2025-07-01
  • Subramanian Sanjay — D-Return (135000 shares) on 2025-07-01
  • Subramanian Sanjay — D-Return (145000 shares) on 2025-07-01
  • Subramanian Sanjay — U-Tender (39701 shares) on 2025-07-01
  • Subramanian Sanjay — D-Return (38500 shares) on 2025-07-01

Open Inozyme Pharma, Inc. (INZY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.